235 related articles for article (PubMed ID: 15939937)
1. Economic grand rounds: the economics of the new medicare drug benefit: implications for people with mental illnesses.
Donohue JM
Psychiatr Serv; 2005 Jun; 56(6):645-7. PubMed ID: 15939937
[No Abstract] [Full Text] [Related]
2. Economic grand rounds: potential effects of the new medicare drug benefit on pricing for psychotropic medications.
Huskamp HA; Shinogle JA
Psychiatr Serv; 2005 Sep; 56(9):1056-8. PubMed ID: 16148317
[No Abstract] [Full Text] [Related]
3. Caught in between: prescription drug coverage of Medicare beneficiaries near poverty.
Shea DG; Stuart BC; Briesacher B
Issue Brief (Commonw Fund); 2003 Aug; (669):1-8. PubMed ID: 12926411
[No Abstract] [Full Text] [Related]
4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
[No Abstract] [Full Text] [Related]
6. Generic versus brand name drugs in psychopharmacology: a pharmacoeconomic perspective.
Emanuele E
South Med J; 2011 Oct; 104(10):715-6. PubMed ID: 21941163
[No Abstract] [Full Text] [Related]
7. Medicare part D and decompensation.
Park JM; Hariprasad R; Park LT
Psychiatr Serv; 2006 May; 57(5):722-3. PubMed ID: 16675773
[No Abstract] [Full Text] [Related]
8. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
[No Abstract] [Full Text] [Related]
9. Affordable prescription drugs--state and federal action.
Ohio Nurses Rev; 2003 Aug; 78(7):4. PubMed ID: 15134064
[No Abstract] [Full Text] [Related]
10. Medication cost-cutting plans burden patients and clinicians.
Albright B
Behav Healthc; 2015; 35(1):20, 22-4. PubMed ID: 25764698
[No Abstract] [Full Text] [Related]
11. The new Medicare prescription-drug legislation.
Altman DE
N Engl J Med; 2004 Jan; 350(1):9-10. PubMed ID: 14702422
[No Abstract] [Full Text] [Related]
12. Mental health in the Medicare Part D drug benefit: a new regulatory model?
Donohue J
Health Aff (Millwood); 2006; 25(3):707-19. PubMed ID: 16684735
[TBL] [Abstract][Full Text] [Related]
13. How does drug coverage vary by insurance type? Analysis of drug formularies in the United States.
Régnier SA
Am J Manag Care; 2014 Apr; 20(4):322-31. PubMed ID: 24884863
[TBL] [Abstract][Full Text] [Related]
14. Chronic conditions and disabilities: trends and issues for private drug plans.
Boccuti C; Moon M; Dowling K
Policy Brief Commonw Fund; 2003 Oct; (680):1-10. PubMed ID: 14562797
[No Abstract] [Full Text] [Related]
15. Dual eligibles with mental disorders and Medicare part D: how are they faring?
Donohue JM; Huskamp HA; Zuvekas SH
Health Aff (Millwood); 2009; 28(3):746-59. PubMed ID: 19414883
[TBL] [Abstract][Full Text] [Related]
16. The new Medicare drug benefit: much ado about little?
Pauly MV
LDI Issue Brief; 2004; 9(4):1-6. PubMed ID: 15035261
[TBL] [Abstract][Full Text] [Related]
17. Improving psychiatric drug benefit management: IV. Experiences of a pharmacy advisory committee.
Gottlieb D; Dubin WR; Ning A; Gardiner GC
Psychiatr Serv; 2004 Nov; 55(11):1210-2. PubMed ID: 15534007
[No Abstract] [Full Text] [Related]
18. Economic grand rounds: the mismanagement of medication management.
Fleishman M
Psychiatr Serv; 2000 Apr; 51(4):457-9. PubMed ID: 10737818
[No Abstract] [Full Text] [Related]
19. A sustainable future?: the role of premium subsidies in Medicare prescription drug plans.
Demchak C
Find Brief; 2007 Jan; 10(2):1-6. PubMed ID: 17302011
[No Abstract] [Full Text] [Related]
20. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
[No Abstract] [Full Text] [Related]
[Next] [New Search]
